Mortgage Blog Incyte shares decline on FDA rejection for updated Jakafi tablet firststargroup March 25, 2023 Incyte's Jakafi drug generated $2.4 billion, or 88% of the company's total revenue in 2022.
Incyte's Jakafi drug generated $2.4 billion, or 88% of the company's total revenue in 2022.
